However, by combining our results with RTOG 9601 and recently published SPPORT study, we can conclude that high-risk prostate cancer patients with BCR post-RP should be treated with pelvic and prostate-bed radiation therapy in conjunction with long-term ADT until the data on systemic-therapy intensification emerge. The gene discussed is BCR; the disease is prostate cancer.